Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients

Leonidas C. Platanias*, Carole B. Miller, Rosemarie Mick, Ronald D. Hart, Howard Ozer, Jan Marie McEvilly, Richard J. Jones, Mark J. Ratain

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

115 Scopus citations


Thirty patients with chemotherapy-induced anemia were treated with recombinant human erythropoietin for 4 weeks. In this dose-escalation study, cohorts of five to eight patients were treated per dose level. The doses of erythropoietin were 25, 50, 100, 200, or 300 IU/kg/d given intravenously for 5 days each week. Of 30 patients, 15 (50%) had a greater than 10% increase of their hemoglobin (Hb) values and were considered responders. At the two highest dose levels, 11 of 13 patients (85%) responded. In the 15 responding patients, the mean Hb level increased by 1.7 g/dL from baseline compared with an average decrease of 1.5 g/dL in the previous cycles of chemotherapy without erythropoietin administration. Recombinant human erythropoietin is effective in ameliorating chemotherapy-induced anemia when administered in adequate doses.

Original languageEnglish (US)
Pages (from-to)2021-2026
Number of pages6
JournalJournal of Clinical Oncology
Issue number11
StatePublished - Nov 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients'. Together they form a unique fingerprint.

Cite this